Roxane's PTAB Challenge To Afinitor Patent Comes Up Empty
The Patent Trial and Appeal Board refused Monday to review a patent related to Novartis AG's blockbuster cancer drug Afinitor, finding that generic drugmaker Roxane Laboratories Inc. had not shown that...To view the full article, register now.
Already a subscriber? Click here to view full article